Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment.

Publication ,  Journal Article
Witherspoon, RP; Storb, R; Ochs, HD; Fluornoy, N; Kopecky, KJ; Sullivan, KM; Deeg, JH; Sosa, R; Noel, DR; Atkinson, K; Thomas, ED
Published in: Blood
August 1981

One-hundred fifty-three recipients of HLA-identical sibling marrow transplants for aplastic anemia or hematologic malignancy were injected with bacteriophage phi X174 (phage), pneumococcal polysaccharide antigen (PPA), or keyhole limpet hemocyanin (KLH). Antibody levels were determined several times in the 6 wk after injection. Multiple regression techniques were used to determine what factors played significant roles in the antibody response. The most significant factors were the time elapsed from transplantation, chronic graft-versus-host disease (GVHD), and antithymocyte globulin (ATG) treatment. All patients had low antibody responses to all antigens in the first 180 days from transplant. Beyond 180 days patients without chronic GVHD showed antibody responses indistinguishable from those of normal donors. However, patients with chronic GVHD had the following impairments: (1) primary response to phage, (2) conversion from IgM to IgG in secondary response to phage, (3) secondary response to KLH, and (4) response to PPA. ATG treatment given to patients either prophylactically or therapeutically for acute GVHD was followed by lower primary responses to phage in the first 180 days and poor ability to switch from IgM to IgG antibody in the secondary response beyond 180 days postgrafting. Other factors did not yield additional significant information about ability to predict antibody responses including diagnosis, conditioning regimen, treatment in or out of laminar air flow rooms, transplantation, pretransplant refractoriness of the recipient to platelet transfusions from random donors, donor age or donor sex, and steroid administration for treatment for prevention of GVHD. The data indicate that, given enough time after transplantation, the ability to produce normal antibody function recovers except in those patients experiencing chronic GVHD.

Duke Scholars

Published In

Blood

ISSN

0006-4971

Publication Date

August 1981

Volume

58

Issue

2

Start / End Page

360 / 368

Location

United States

Related Subject Headings

  • Transplantation, Homologous
  • Time Factors
  • T-Lymphocytes
  • Streptococcus pneumoniae
  • Immunology
  • Humans
  • Hemocyanins
  • Hemagglutinins
  • Graft vs Host Reaction
  • Chronic Disease
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Witherspoon, R. P., R. Storb, H. D. Ochs, N. Fluornoy, K. J. Kopecky, K. M. Sullivan, J. H. Deeg, et al. “Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment.Blood 58, no. 2 (August 1981): 360–68.
Witherspoon RP, Storb R, Ochs HD, Fluornoy N, Kopecky KJ, Sullivan KM, Deeg JH, Sosa R, Noel DR, Atkinson K, Thomas ED. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood. 1981 Aug;58(2):360–368.

Published In

Blood

ISSN

0006-4971

Publication Date

August 1981

Volume

58

Issue

2

Start / End Page

360 / 368

Location

United States

Related Subject Headings

  • Transplantation, Homologous
  • Time Factors
  • T-Lymphocytes
  • Streptococcus pneumoniae
  • Immunology
  • Humans
  • Hemocyanins
  • Hemagglutinins
  • Graft vs Host Reaction
  • Chronic Disease